Novartis "can never be done" when it comes to major acquisitions in its sector, CEO Vas Narasimhan told CNBC.

Vas Narasimhan, CEO of pharmaceuticals company, Novartis, discusses the company's latest $12 billion acquisition of Avidity Biosciences, and ongoing negotiations with the U.S.…

Novartis "can never be done" when it comes to major acquisitions in its sector, CEO Vas Narasimhan told CNBC.